Is OCUL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OCUL. It does not provide personalized investment advice.

OCUL (Ocular Therapeutix, Inc.) Stock Analysis - Financials

Ocular Therapeutix, Inc. (OCUL) is a publicly traded Healthcare sector company. As of July 26, 2026, OCUL trades at $8.51 with a market cap of $1.86B and a P/E ratio of -5.91. OCUL moved -1.28% today. Year to date, OCUL is -30.29%; over the trailing twelve months it is -28.65%. Its 52-week range spans $5.79 to $16.44. Analyst consensus is strong buy with an average price target of $25.50. Rallies surfaces OCUL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are OCUL's key financials?

OCUL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. OCUL recently traded at $8.51. Market cap is $1.86B. P/E ratio is -5.91. Revenue is $52.04M.

OCUL Key Metrics

Key financial metrics for OCUL
Metric	Value
Price	$8.51
Market Cap	$1.86B
P/E Ratio	-5.91
EPS	$-1.44
Dividend Yield	0.00%
52-Week High	$16.44
52-Week Low	$5.79
Volume	0
Avg Volume	0
Revenue (TTM)	$52.04M
Net Income	$-290.50M
Gross Margin	87.24%

OCUL Analyst Consensus

9 analysts cover OCUL: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.50.

Common questions about OCUL

What are OCUL's key financials?: OCUL financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. OCUL recently traded at $8.51. Market cap is $1.86B. P/E ratio is -5.91. Revenue is $52.04M.
Is OCUL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OCUL. It does not provide personalized investment advice.